ArticleScientific reports2025
Molecular recognition of natural compounds by MR1 and their implication in MAIT cell activation elucidated through McMD-based dynamic docking simulations.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Major histocompatibility complex class I-related protein 1 (MR1), presents bacteria-derived ligands to T cell receptors (TCRs) as antigens as a defense against bacterial infections through activation of mucosal-associated invariant T cells (MAIT cells). Since mammals do not produce riboflavin (RBF, vitamin B2) themselves, unlike bacteria, MR1 can present the intermediates of RBF synthesis as a marker of non-self to initiate an immune response. Here, we have performed multicanonical molecular dynamics-based dynamic docking simulations to analyze the binding mechanism of RBF and two of its derivatives, photolumazine I (PLI) and III (PLIII) with MR1. We found that PLI and PLIII bind with high specificity in a manner similar to a known high-affinity ligand, RL-6-Me-7-OH. In contrast, RBF binds in multiple less specific, non-productive configurations. Subsequent structural analyses revealed that PLI and PLIII support productive TCR engagement and MAIT cell activation, while RBF fails to activate MAIT cells. Consequently, an immune response is triggered against PLI and PLIII, but not against RBF. These findings uncover the distinct binding mechanisms between the three compounds and MR1 and highlight their differential effects on MAIT cell activation in the context of bacterial infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.